<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863330</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636885</org_study_id>
    <secondary_id>STLMC-L-0839</secondary_id>
    <nct_id>NCT00863330</nct_id>
  </id_info>
  <brief_title>Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Treating lymphocytes in the laboratory may help the lymphocytes kill more tumor&#xD;
      cells when they are put back in the body. Aldesleukin may stimulate the lymphocytes to kill&#xD;
      tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving laboratory-treated lymphocytes and aldesleukin together with&#xD;
      cyclophosphamide and fludarabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well laboratory-treated autologous lymphocytes&#xD;
      and aldesleukin work when given after cyclophosphamide and fludarabine in treating patients&#xD;
      with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the ability of treatment with short-term cultured autologous&#xD;
           tumor-infiltrating lymphocytes (TIL) in combination with high-dose aldesleukin after a&#xD;
           nonmyeloablative lymphocyte-depleting preparative regimen comprising cyclophosphamide&#xD;
           and fludarabine phosphate to mediate tumor regression in patients with metastatic&#xD;
           melanoma.&#xD;
&#xD;
        -  Determine the toxicity of this treatment regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the rate of repopulation of the young TIL cells.&#xD;
&#xD;
        -  Establish in vitro immunological correlates that predict in vivo persistence and&#xD;
           clinical response.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Conditioning regimen: Patients receive cyclophosphamide IV over 1 hour on days -7 and -6&#xD;
           and fludarabine phosphate IV over 30 minutes on days -5 to -1.&#xD;
&#xD;
        -  Tumor-infiltrating lymphocyte (TIL) infusion and high-dose aldesleukin: Patients receive&#xD;
           short-term cultured autologous TIL IV over 20-30 minutes on day 0. Patients also receive&#xD;
           high-dose aldesleukin IV over 15 minutes every 8 hours on days 0-4.&#xD;
&#xD;
      Patients with stable disease, partial response, or recurrent disease after initial response&#xD;
      may receive 1 additional course of treatment (as above) beginning 8 weeks after completion of&#xD;
      aldesleukin.&#xD;
&#xD;
      Blood samples are collected at baseline, at 1 week and 1 month after TIL infusion, and then&#xD;
      periodically thereafter for research studies. Samples are analyzed for differences in&#xD;
      function and phenotype prior to and after TIL infusion. The immunological correlates of&#xD;
      treatment are also evaluated using FACS, cytokine release assays, ELISPOT assays, flow&#xD;
      cytometry, and PCR. TIL that are cryopreserved at the time of infusion are analyzed to&#xD;
      determine cell phenotype and function; correlation of in vitro characteristics of the infused&#xD;
      cells with in vivo antitumor activity; and the activity, specificity, and telomere length&#xD;
      using flow FISH.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4-6 weeks, every 3 months for 1&#xD;
      year, every 6 months for 2 years, and then annually for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    administrative decision- PI retired and treating physician left the institution&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective</measure>
    <time_frame>4-6 weeks after completion of TIL</time_frame>
    <description>Determine the ability of autologous cells infused with minimal in vitro culture in conjunction with high dose interleukin -2 (IL-2) following non-myeloablative lymphodepleting preparative regimen to mediate tumor regression in patients with metastatic melanoma.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Determine toxicity of treatment regimen.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor Infiltrating Lymphocytes (TIL)</intervention_name>
    <description>Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.</description>
    <arm_group_label>Determine toxicity of treatment regimen.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma&#xD;
&#xD;
          -  Refractory to standard treatment including high-dose aldesleukin (IL-2), unless&#xD;
             previously ineligible for or refused IL-2&#xD;
&#xD;
          -  Measurable disease with ≥ 1 lesion that is resectable for tumor-infiltrating&#xD;
             lymphocyte generation&#xD;
&#xD;
          -  Patients with ≥ 1 brain metastases &lt; 1 cm each, or 1-2 brain metastases &gt; 1 cm are&#xD;
             eligible provided they have been treated and stable for ≥ 3 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC &gt; 1,000/mm^3 (without filgrastim support)&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Serum ALT/AST &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Total bilirubin ≤ 2 mg/dL (&lt; 3 mg/dL in patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.6 mg/dL&#xD;
&#xD;
          -  LVEF &gt; 45% in patients meeting the following criteria:&#xD;
&#xD;
               -  Clinically significant atrial and/or ventricular arrhythmias, including, but not&#xD;
                  limited to, atrial fibrillation, ventricular tachycardia, or second- or&#xD;
                  third-degree heart block&#xD;
&#xD;
               -  At least 60 years of age&#xD;
&#xD;
          -  FEV_1 &gt; 60% in patients meeting the following criteria:&#xD;
&#xD;
               -  Prolonged history of cigarette smoking&#xD;
&#xD;
               -  Symptoms of respiratory dysfunction&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No HIV or hepatitis B or C positivity&#xD;
&#xD;
          -  No form of primary immunodeficiency (e.g., severe combined immunodeficiency disease or&#xD;
             AIDS)&#xD;
&#xD;
          -  No opportunistic infections&#xD;
&#xD;
          -  No active systemic infections&#xD;
&#xD;
          -  No history of severe immediate hypersensitivity reaction to any of the agents used in&#xD;
             this study&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
          -  No myocardial infarction, cardiac arrhythmias, or positive stress thallium or&#xD;
             comparable test&#xD;
&#xD;
          -  No history of coronary revascularization or ischemic symptoms&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease&#xD;
&#xD;
          -  No other active major medical illness of the cardiovascular, respiratory, or immune&#xD;
             system&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy (alopecia or vitiligo allowed)&#xD;
&#xD;
          -  At least 6 weeks since prior ipilimumab&#xD;
&#xD;
               -  Must have normal colonoscopy with normal colonic biopsies&#xD;
&#xD;
          -  At least 4 weeks since prior systemic therapy&#xD;
&#xD;
          -  Minor surgical procedures within the past 3 weeks allowed provided all toxicities have&#xD;
             recovered to ≤ grade 1&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
          -  No other concurrent experimental agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Hanson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan S. Treisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <results_first_submitted>December 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2014</results_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aurora Health Care</investigator_affiliation>
    <investigator_full_name>Jackie Blundon, MS, CIP</investigator_full_name>
    <investigator_title>Research Regulatory Specialist</investigator_title>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>14 participants were enrolled. For those, 8 were screen failures and 6 started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Determine Toxicity of Treatment Regimen.</title>
          <description>Tumor Infiltrating Lymphocytes (TIL): Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated early due to administra</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Determine Toxicity of Treatment Regimen.</title>
          <description>Tumor Infiltrating Lymphocytes (TIL): Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 or over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Objective</title>
        <description>Determine the ability of autologous cells infused with minimal in vitro culture in conjunction with high dose interleukin -2 (IL-2) following non-myeloablative lymphodepleting preparative regimen to mediate tumor regression in patients with metastatic melanoma.</description>
        <time_frame>4-6 weeks after completion of TIL</time_frame>
        <population>Study was terminated for administrative reasons. complete data was not collected and no data analysis was completed</population>
        <group_list>
          <group group_id="O1">
            <title>Determine Toxicity of Treatment Regimen.</title>
            <description>Tumor Infiltrating Lymphocytes (TIL): Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Objective</title>
          <description>Determine the ability of autologous cells infused with minimal in vitro culture in conjunction with high dose interleukin -2 (IL-2) following non-myeloablative lymphodepleting preparative regimen to mediate tumor regression in patients with metastatic melanoma.</description>
          <population>Study was terminated for administrative reasons. complete data was not collected and no data analysis was completed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Determine Toxicity of Treatment Regimen.</title>
          <description>Tumor Infiltrating Lymphocytes (TIL): Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was ended early, before substantial data could be collected, due to Investigators retiring/leaving the institution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>IIR regulatory specialist</name_or_title>
      <organization>Aurora Health Care</organization>
      <phone>414-219-7886</phone>
      <email>jackie.blundon@aurora.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

